Back to discover
Disease

Cutaneous lupus erythematosus

Late-stage therapeutic development

Also known as lupus erythematosus, cutaneous.

24
Clinical trials
12
Associated genes
3
Related proteins
Current focus
Therapeutic developmentToll-like 7 biologyToll-like 9 biology
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Moderate
Key developments
  • 5 clinical trials expected to report results, the earliest in Q2 2027.
Upcoming Milestones
Clinical Milestones11View all 11
Results posted 4
Results expected 5
Other updates 2
+3 more in the activity timeline below
Activity timeline11

Clinical trials

14 sponsors · 3 new · 0 completed in the last 12 months (net +2)

The current development programme across all trial phases.

Clinical programme
24
All trials
6
Active
18
Late-stage
6
Completed
Late-stage studies

A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus

Phase 3 · Recruiting · Janssen Research & Development, LLC

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obinutuzumab in Patients With ISN/RPS 2003 Class III or IV Lupus Nephritis

Phase 3 · Active, not recruiting · Hoffmann-La Roche

A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Clinical Trial and Open-Label Extension Study of Sirolimus in Patients With Systemic Lupus Erythematosus-Associated Immune Thrombocytopenia

Phase 2/3 · Recruiting · Chinese SLE Treatment And Research Group

A Phase 3, Randomized, Double-Blind,Placebo-Controlled Parallel Study to Evaluate the Efficacy and Safety of Enpatoran in Participants With Active Cutaneous Manifestations of Lupus Erythematosus With or Without Systemic Disease Receiving Standard of Care (ELOWEN-2)

Phase 3 · Recruiting · EMD Serono Research & Development Institute, Inc.

A Randomized, Double-blind, Placebo-controlled Multicenter Phase 3 Study to Evaluate Efficacy, Safety and Tolerability of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2)

Phase 3 · Active, not recruiting · Novartis Pharmaceuticals

A Randomized, Double-blind, Parallel Group, Placebo-controlled, Multicenter Phase 3 Trial to Evaluate Efficacy, Safety and Tolerability of Ianalumab on Top of Standard-of-care Therapy in Participants With Active Lupus Nephritis (SIRIUS-LN).

Phase 3 · Active, not recruiting · Novartis Pharmaceuticals
Recruiting

A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus

Phase 3 · Recruiting · Janssen Research & Development, LLC

A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Clinical Trial and Open-Label Extension Study of Sirolimus in Patients With Systemic Lupus Erythematosus-Associated Immune Thrombocytopenia

Phase 2/3 · Recruiting · Chinese SLE Treatment And Research Group

A Phase 3, Randomized, Double-Blind,Placebo-Controlled Parallel Study to Evaluate the Efficacy and Safety of Enpatoran in Participants With Active Cutaneous Manifestations of Lupus Erythematosus With or Without Systemic Disease Receiving Standard of Care (ELOWEN-2)

Phase 3 · Recruiting · EMD Serono Research & Development Institute, Inc.
Recently completed

A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase III Study Evaluating the Efficacy and Safety of Anifrolumab in Asian Participants With Active Systemic Lupus Erythematosus

Phase 3 · Completed · AstraZeneca

A Randomized Open-label Study to Evaluate the Efficacy and Safety of Tacrolimus and Corticosteroids in Comparison With Mycophenolate Mofetil and Corticosteroids in Subjects With Class III/IV±V Lupus Nephritis

Phase 3 · Completed · The University of Hong Kong

A Two-cohort, Open-label, Single Arm, Multicenter Study to Evaluate Efficacy, Safety and Tolerability, PK and PD, of Emapalumab in Children and Adults With MAS in Still's Disease or With MAS in Systemic Lupus Erythematous

Phase 3 · Completed · Swedish Orphan Biovitrum

A Multi-Center, Open-Label Study to Evaluate Safety, Efficacy and Pharmacokinetics of Belimumab Plus Standard Therapy in Chinese Paediatric Patients With Active Systemic Lupus Erythematosus (SLE)

Phase 4 · Completed · GlaxoSmithKline

SGLT2 Inhibitors Between Reno Protective Effects and Impact on Bone and Mineral Disease Among Diabetic and Non- Diabetic Lupus Nephritis Patients

Phase 4 · Completed · Mansoura University

Study of the Cardio Renal Effects of SGLT2 Inhibitors Among Diabetic and Non-diabetic Lupus Nephritis Patients

Phase 4 · Completed · Mansoura University

Associated genes

12 matches

Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.

TLR70.45TLR90.43CLEC4C0.36NCF20.33ZNF3650.31MRPL30.29TIMP30.29TRPC70.29SENP60.29TNFRSF190.28ARAP20.28DTHD10.28

Disease biology

3 matches

Proteins whose encoding gene is associated with this disease, reached through the canonical gene→disease graph. Number shows the gene's association score.

Toll-like receptor 7via TLR70.45Toll-like receptor 9via TLR90.43Metalloproteinase inhibitor 3via TIMP30.29

Reference

Authoritative identity, definition & identifiers.

Synonyms

lupus erythematosus, cutaneous

References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.